Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
94 Cards in this Set
- Front
- Back
biopharmaceutics
|
the study of the relationship between the nature and intensity of the drugs biological effect and various drug formulation or administration factors
|
|
pharmacokinetics
|
a study of the time course of drug of absorption, distribution, metabolism, and excretion
|
|
Disposition
|
what occurs after the drug is absorbed (distribution & elimination)
|
|
Absorption
|
process by which unchanged drug proceeds from side of administration to sight of measurement within the body; the penetration of free drug molecules through a biological membrane
|
|
distribution
|
process of delivering drugs into body tissues and fluids following absorption
|
|
metabolism
|
chemical alteration of the drug in the body to a different chemical species
|
|
excretion
|
removal of intact drug or metabolite from the body
|
|
elimination
|
irreversible removal of drug from the body by all routes of elimination; the combined effort of biotransformation and excretion
|
|
absorption is dependent on
|
solubility, molecular weight, permeability
|
|
clinical pharmacokinetics
|
the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs and an individual patient
|
|
objectives of clinical pharmacokinetics
|
1. initial design of drug ghosting regiment 2. refinement of dosing regimen based on serum samples 3. pharmcokinetic work-up 4. research
|
|
Pharmacodynamics
|
relationship between the drug concentration at the site of the action and pharmacologic response ; what the drug does to the body
|
|
therapeutic drug monitoring
|
the utilization of plasma drug concentrations and clinical data to individualize and optimize a patient's drug therapy
|
|
bioavailability
|
the percentage or fraction of the administered dose which reaches the systemic circulation
|
|
bioequivalence
|
comparison of bioavailabilities of different formulations, drug products, or batches of the same drug product
|
|
duration of action
|
the time the plasma concentration is above the MEC
|
|
lag time
|
the time that it takes for drugs to begin being absorbed
|
|
onset time
|
the time it takes the plasma drug concentration to reach the MEC
|
|
the intensity of the drug plasma concentration is proportional to
|
the number of drug receptor sites occupied
|
|
drug dosing regimen
|
dose, route, interval, etc
|
|
bioavailability (F) <1 because
|
absorption incomplete, degradation in GI tract, first pass metabolism
|
|
zero order
|
the amount of drug decreases at a constant rate
|
|
first order
|
the amount of drug decreases at a rate that is proportional to the amount of drug
|
|
nine routes of drug administration
|
IV bolus, IV infusion, IM, SC, SL, PO, PR, transdermal, inhalation
|
|
reasons to give drug intravenously
|
controlled rate, rapid response, drug has absorption difficulties or stability problems
|
|
reasons to give drugs orally
|
avoid high early toxic levels, avoid rapid allergic reactions, easy to administer, drug problems with physical or chemical stability of formulation
|
|
for a drug to be absorbed, it must first…
|
be dissolved in fluid at the absorption site (cannot pass through membrane in particulate form)
|
|
the most common rate limiting step in oral absorption
|
dissolution (there is also disintegration & GI transfer)
|
|
absorption of drug not complete
|
chemical nature of drug (very polar), dosage form, physiology of the patient
|
|
transcellular absorption
|
passage of molecule through cell membrane
|
|
paracellular absorption
|
that passage of molecules through pores in membrane
|
|
what form of the drug is absorbed better and why
|
unionized form, can cross membranes much easier (more lipid soluble)
|
|
the most common method for drug absorption
|
passive diffusion
|
|
passive diffusion
|
drug goes from area of high concentration to the area of low concentration
|
|
acidic drugs tend to be absorbed from
|
the stomach (low pH) *HA
|
|
basic drugs tend to be absorbed from
|
the intestine (high pH) *B
|
|
active transport
|
specialized transport mechanism whereby drugs are moved against a concentration gradient, requires a carrier, requires energy
|
|
drugs which utilize active transport are analogues of
|
endogenous substances
|
|
mechanisms of absorption
|
passive diffusion, active transport, facilitated diffusion, ion pair formation
|
|
facilitated diffusion
|
carrier mediated, does not require energy, can be saturated and and inhibited, moves along concentration gradient
|
|
ion pair formation
|
ionized drug links up with oppositely chared ion, forming a neutral pair (cation drug + anion carrier)
|
|
stomach pH
|
1 to 3
|
|
small intestine pH
|
5 to 8
|
|
large intestine pH
|
6 to 7
|
|
acidic drugs are soluble in the _____ and basic drugs are soluble in the ______
|
stomach, intestine
|
|
major area for absorption of drugs and nutrients
|
small intestine (huge surface area)
|
|
Gastic emptying rate
|
the rate of movement of the GI mass from the stomach to the duodenum
|
|
factors that alter gastric emptying rate
|
food, drug coadministration, body position, physiological status of patient
|
|
factors affecting drug distribution
|
cardiac output, plasma protein binding, chemical structure of drug
|
|
perfusion ratio
|
blood flow /tissue mass
|
|
highly perfused tissues
|
spleen, kidney, gut, pancreas, brain, heart, and lungs
|
|
__ of cardiac output is delivered to tissues that comprise less than __ of the body weight
|
3/4, 1/10
|
|
stronger acids --> _____ distribution
|
narrower
|
|
drug distribution patterns
|
remains within the vascular compartment, uniformly distributed through body water, concentrated in a particular tissue, non uniform distribution
|
|
drugs in the brain can only be eliminate by
|
the blood
|
|
drug penetration to the placenta is greater in
|
the third trimester
|
|
Ion trapping of _____ drugs occurs in the milk
|
basic
|
|
proteins involved in binding drug
|
albumin, alpha1 glycoprotein, lipoproteins
|
|
albumin
|
responsible for maintaining osmotic pressure of the blood and for transport of endogenous substances
|
|
binds to specific site on albumin
|
acidic drugs
|
|
extent to which a drug binds to albumin depends on
|
a affinity of drug to albumin, number of binding sites on albumin for particular drug, concentration of drug, concentration of albumin
|
|
alpha1 acid glycoprotein primarily binds
|
basic drugs
|
|
liver disease causes
|
decrease albumin concentration due to decreased protein synthesis
|
|
as free drug increases, drug distribution
|
increases
|
|
restrictive elimination
|
process of elimination which occurs only to unbound drugs
|
|
characteristics of restrictive elimination
|
drug tightly bound to protein, small plasma clearance, small hepatic extraction ratio
|
|
non restrictive elimination
|
process of elimination which occurs to protein bound rugs
|
|
characteristics of non restrictive elimination
|
drug weakly bound to protein, high liver extraction
|
|
major route for polar drug excretion
|
renal
|
|
mechanisms of renal secretion
|
glomerular filtration, secretion, reabsorption
|
|
glomerular filtration
|
unidirectional process of filtration through porous capillaries of bowman's capsule
|
|
secretion
|
active transport of drug from blood into urine, occurs in proximal tubule
|
|
reabsorption
|
mechanism for reuptake of drug, offsets effect of filtration, occurs in distal part of tubule
|
|
renal blood flow
|
1200mL/min or 1730 L/day
|
|
factors that affect renal excretion
|
drug protein binding, partition coefficient, urine PH, molecular size, active secretion properties
|
|
total body clearance
|
the volume of fluid cleared of drug per unit time by the entire body
|
|
organ clearance
|
measure of an organ's ability to clear a substance
|
|
renal clearance
|
the volume of plasma that is cleared of drug per unit time through the kidney
|
|
max renal clearance
|
650mL/min
|
|
if Clr is between 120-650mL/min
|
filtration & secretion taking place
|
|
if Clr is between 0-120mL/min
|
filtration & reabsorption are taking place
|
|
used to estimate renal function
|
inulin, creatinine
|
|
biliary excretion
|
drugs can be excreted from the liver into the bile by active transport
|
|
enterohepatic circulation
|
cycle in which the drug is absorbed from GI, excreted into bile, & reabsorbed
|
|
properties for biliary excretion
|
MW >500, strong polar group, active transport
|
|
three carriers for biliary excretion
|
organic anions, organic cations, non-ionized
|
|
biotransformation
|
chemical modification of parent drugs resulting in loss of drug from body
|
|
phase one reactions
|
oxidative, reduction, hydrolysis
|
|
oxidative reactions
|
aromatic hydoxylation, side chain hydroxylation, N- O- S-dealkylation, deamination, sulfoxidation, N-oxidation, N-hydoxylation
|
|
reduction reactions
|
azoreduction, nitroreduction, alcohol dehydrogenase
|
|
hydrolysis reactions
|
ester hydolysis, amide hydrolysis
|
|
phase two reactions
|
glucuronide conjugation, peptide conjugation, methylation, acetylation, sulfate conjugation, glutatione conjugation
|
|
glucuronide conjugation
|
esther glucoronide, ester glucoronide, amide glucuronide
|
|
major site of drug metabolism
|
liver
|